Marc Blaustein
Geen lopende functies
Vermogen: 2 519 $ op 29-02-2024
Profiel
Marc B.
Blaustein founded Akashi Therapeutics Inc. Mr. Blaustein is former Chief Executive Officer at Akashi Therapeutics Inc, former Chief Executive Officer of Ned Biosystems, Inc., former Chief Operating, Financial & Accounting Officer at Finch Therapeutics Group, Inc., former Founding Partner of Northbridge Consulting, former Head-Business Development of Genetics Institute LLC, former SVP-Manufacturing, Process & Commercial Operations at Dyax Corp.
and former Head-Business Development for Guide Therapeutics, Inc.
Marc B.
Blaustein received a graduate degree from Harvard University and an undergraduate degree from the University of Pennsylvania.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
10-04-2023 | 933 ( 0.06% ) | 2 519 $ | 29-02-2024 |
Eerdere bekende functies van Marc Blaustein
Bedrijven | Functie | Einde |
---|---|---|
FINCH THERAPEUTICS GROUP, INC. | Director of Finance/CFO | 15-05-2023 |
Guide Therapeutics, Inc.
Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | Corporate Officer/Principal | 01-01-2021 |
Ned Biosystems, Inc.
Ned Biosystems, Inc. BiotechnologyHealth Technology Ned Biosystems, Inc. is a clinical-stage company based in Cambridge, MA. The company is focused on developing cancer treatments with the goal of providing uncommon therapies that help patients achieve "No Evidence of Disease." | Chief Executive Officer | 01-01-2019 |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Chief Executive Officer | 01-01-2017 |
DYAX CORP. | Corporate Officer/Principal | 01-01-2009 |
Opleiding van Marc Blaustein
Harvard University | Graduate Degree |
University of Pennsylvania | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
FINCH THERAPEUTICS GROUP, INC. | Health Services |
Bedrijven in privébezit | 6 |
---|---|
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Dyax Corp.
Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Health Technology |
Ned Biosystems, Inc.
Ned Biosystems, Inc. BiotechnologyHealth Technology Ned Biosystems, Inc. is a clinical-stage company based in Cambridge, MA. The company is focused on developing cancer treatments with the goal of providing uncommon therapies that help patients achieve "No Evidence of Disease." | Health Technology |
Guide Therapeutics, Inc.
Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | Health Technology |
Northbridge Consulting |